Anand Sharma1, Deshveer S Babra2, Priya V Joshi2, Marcia Hall2, Andrew Gogbashian3, Nikhil Vasdev4, Magdalene Joseph2, Amir Yazdan2, Edward Kanfer5. 1. Department of Medical Oncology, Mount Vernon Cancer Centre, London, U.K. anand.sharma3@nhs.net. 2. Department of Medical Oncology, Mount Vernon Cancer Centre, London, U.K. 3. Department of Radiology, Paul Strickland Scanner Centre, London, U.K. 4. Department of Urology and Surgery, Lister Hospital, East and North Herts NHS Trust, Stevenage, U.K. 5. Department of Haematology, Hammersmith Hospital, Imperial College Healthcare Trust, London, U.K.
Abstract
BACKGROUND/AIM: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs. PATIENTS AND METHODS: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes. RESULTS: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2nd line chemotherapy was 17.3 months. Fourteen patients hadMedian survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance. CONCLUSION: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT. Copyright
BACKGROUND/AIM: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs. PATIENTS AND METHODS: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes. RESULTS: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2nd line chemotherapy was 17.3 months. Fourteen patients hadMedian survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance. CONCLUSION: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT. Copyright
Authors: J Beyer; A Kramar; R Mandanas; W Linkesch; A Greinix; J P Droz; J L Pico; A Diehl; C Bokemeyer; H J Schmoll; C R Nichols; L H Einhorn; W Siegert Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: Anand Sharma; Constantine Alifrangis; Marina Milic; Marcia Hall; Nikhil Vasdev; Peter Wilson; Andrew Gogbashian; David Hrouda; Daniel Berney; Jonathan Shamash Journal: Anticancer Res Date: 2019-09 Impact factor: 2.480
Authors: H-J Schmoll; C Kollmannsberger; B Metzner; J T Hartmann; N Schleucher; P Schöffski; J Schleicher; O Rick; J Beyer; D Hossfeld; L Kanz; W E Berdel; R Andreesen; C Bokemeyer Journal: J Clin Oncol Date: 2003-10-20 Impact factor: 44.544
Authors: Lawrence H Einhorn; Stephen D Williams; Amy Chamness; Mary J Brames; Susan M Perkins; Rafat Abonour Journal: N Engl J Med Date: 2007-07-26 Impact factor: 91.245